Want to see HURA full AI Analyst Report?

TuHURA Biosciences (HURA) Price & Analysis

1,007 Followers

HURA Stock Chart & Stats

$2.92

-$0.03(-0.55%)

At close: Jan 08 4:00 PM EST

$2.92

-$0.03(-0.55%)

Day’s Range― - ―

52-Week Range$0.41 - $3.90

Previous CloseN/A

Volume116.05K

Average Volume (3M)215.15K

Market Cap

$149.02M

Enterprise Value$135.53M

Total Cash (Recent Filing)$6.30M

Total Debt (Recent Filing)$456.93K

Price to Earnings (P/E)―

Beta1.58

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding63,682,530

10 Day Avg. Volume212,396

30 Day Avg. Volume215,145

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.73

Price to Sales (P/S)0.00

P/FCF Ratio-1.31

Enterprise Value/Market Cap0.91

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.77K

Enterprise Value/Ebitda-4.49

Forecast

1Y Price Target

$8.00

Price Target Upside173.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

IFx-2.0 Clinical And Regulatory PotentialOrphan Drug Designation for IFx-2.0 in advanced cutaneous melanoma, coupled with prior responses in anti-PD1–refractory patients and the absence of IFx-2.0 in valuation models, points to meaningful upside if clinical readouts confirm benefit.

Listing ComplianceRegaining compliance with NASDAQ listing rules reduces delisting risk and restores market visibility, which could improve liquidity and attract institutional interest.

Pipeline DiversificationMultiple development programs, including a Phase 3 Merkel cell carcinoma study and an antibody-drug conjugate nearing clinical testing, create several potential value drivers and lessen reliance on any single program.

Bears Say

Operational And Financing RiskSignificant operational setbacks and ongoing financing needs increase execution and funding risk, which can put sustained downward pressure on the stock if capital access remains constrained.

Regulatory Designation MismatchA mismatch between the Orphan Drug Designation indication and the Phase 3 trial population creates uncertainty about regulatory strategy and the practical impact of the designation on development plans.

TuHURA Biosciences News

TuHURA Biosciences files IND application with FDA for study of TBS-2025

TuHURA Biosciences (HURA) announced that it has filed an Investigational New Drug application with the U.S. FDA for...

26d ago

HURA

TuHURA Biosciences Expands Use of Revolving Credit Facility

TuHURA Biosciences ( ($HURA) ) has provided an update. On April 21, 2026, TuHURA Biosciences, Inc. entered into...

4d ago

HURA

TuHURA Sets 2026 Virtual Annual Meeting, Proposal Deadlines

TuHURA Biosciences ( ($HURA) ) has shared an update. TuHURA Biosciences’ board has set August 18, 2026, as...

24d ago

HURA

TuHURA Biosciences Draws on New $50M Credit Facility

TuHURA Biosciences ( ($HURA) ) has provided an announcement. On April 21, 2026, TuHURA Biosciences, Inc. entered into...

1M ago

HURA

Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks

Tuhura Biosciences, Inc. (HURA) has disclosed a new risk, in the Debt & Financing category. The analyst notes...

2M ago

HURA

TuHURA Biosciences Extends Cash Runway and Advances Pipeline

TuHURA Biosciences ( ($HURA) ) just unveiled an update. On May 15, 2026, TuHURA Biosciences reported first-quarter 2026...

2M ago

HURA

TuHURA Biosciences initiated with an Outperform at Citizens

Citizens initiated coverage of TuHURA Biosciences (HURA) with an Outperform rating and $9 price target TuHURA is a...

3M ago

HURA

TuHURA Biosciences Secures $50 Million Credit Facility

TuHURA Biosciences ( ($HURA) ) has provided an update. On April 21, 2026, TuHURA Biosciences, Inc. entered into...

3M ago

HURA

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $7 price target The...

3M ago

HURA

TuHURA Biosciences Approves 2025 Executive Compensation Adjustments

TuHURA Biosciences ( ($HURA) ) has shared an announcement. On April 2, 2026, TuHURA Biosciences’ board compensation committee...

3M ago

HURA

TuHURA Biosciences files INDA for TBS-2025 in blood-related cancers

TuHURA Biosciences (HURA) has filed an Investigational New Drug Application, or INDA, with the FDA’s Division of Hematologic...

5M ago

HURA

VOO vs. VTI vs. VTWO: Which Vanguard ETF Offers the Best Upside in 2026?

With markets shifting and investors looking ahead to 2026, choosing the right Vanguard ETF could make a big...

5M ago

VOO

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/6/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 1.40% in...

5M ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/4/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.28% in...

5M ago

IMA

HURA FAQ

What was TuHURA Biosciences’s price range in the past 12 months?

TuHURA Biosciences lowest stock price was $0.41 and its highest was $3.90 in the past 12 months.

What is TuHURA Biosciences’s market cap?

TuHURA Biosciences’s market cap is $149.02M.

When is TuHURA Biosciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were TuHURA Biosciences’s earnings last quarter?

Currently, no data Available

Is TuHURA Biosciences overvalued?

According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TuHURA Biosciences pay dividends?

TuHURA Biosciences does not currently pay dividends.

What is TuHURA Biosciences’s EPS estimate?

TuHURA Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does TuHURA Biosciences have?

TuHURA Biosciences has 63,682,530 shares outstanding.

What happened to TuHURA Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of TuHURA Biosciences?

Currently, no hedge funds are holding shares in HURA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

TuHURA Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-153.99%

Trailing 12-Months

Asset Growth

102.92%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

TuHURA Biosciences

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

TuHURA Biosciences (HURA) Earnings & Revenues

Historic Earnings Reports

HURA Stock 12 Month Forecast

Average Price Target

$8.00

▲(173.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.953846153846154,3.457692307692308,3.9615384615384617,4.4653846153846155,4.969230769230769,5.473076923076923,5.976923076923077,6.480769230769231,6.984615384615385,7.4884615384615385,7.992307692307692,8.496153846153845,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.876923076923077,3.303846153846154,3.730769230769231,4.157692307692308,4.584615384615384,5.0115384615384615,5.438461538461539,5.865384615384615,6.292307692307692,6.719230769230769,7.1461538461538465,7.573076923076923,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.8000000000000003,3.1500000000000004,3.5,3.85,4.2,4.55,4.9,5.25,5.6,5.95,6.3,6.6499999999999995,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.756,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.518,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >